EXFY:NASDAQExpensify, Inc. Analysis
Data as of 2026-04-01 - not real-time
$0.87
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Expensify’s stock is trading well below its short‑term and long‑term moving averages, with the price under the 20‑day, 50‑day and 200‑day SMAs, underscoring a bearish technical backdrop. The RSI sits in the mid‑40s, suggesting neither extreme oversold nor overbought conditions, while the MACD histogram has turned positive, offering a modest bullish signal amid overall weakness. Volatility is exceptionally high, exceeding 100% over the past month, and beta is above one, indicating the stock moves more aggressively than the market.
On the fundamentals side, the company posted a revenue decline year‑over‑year but generated solid free cash flow and operating cash flow, a rare positive in a loss‑making SaaS business. Valuation metrics are compelling: the price‑to‑book is well under one, the forward P/E is far below the industry average, and a discounted cash flow model implies a fair value more than four times the current price, pointing to a sizeable upside potential. However, margins remain thin, profitability is negative, and the balance sheet shows modest leverage. Overall, the stock offers a high‑risk, high‑reward profile, with technical weakness offset by a deep valuation gap and cash generation.
On the fundamentals side, the company posted a revenue decline year‑over‑year but generated solid free cash flow and operating cash flow, a rare positive in a loss‑making SaaS business. Valuation metrics are compelling: the price‑to‑book is well under one, the forward P/E is far below the industry average, and a discounted cash flow model implies a fair value more than four times the current price, pointing to a sizeable upside potential. However, margins remain thin, profitability is negative, and the balance sheet shows modest leverage. Overall, the stock offers a high‑risk, high‑reward profile, with technical weakness offset by a deep valuation gap and cash generation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below key moving averages
- High short‑term volatility
- Bullish MACD histogram but overall bearish trend
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation upside relative to DCF
- Positive free cash flow generation
- Low price‑to‑book and forward P/E versus peers
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Deep valuation discount and potential for margin improvement
- Scalable SaaS platform with expanding user base
- Resilient cash position despite modest debt
Key Metrics & Analysis
Financial Health
Revenue Growth-4.90%
Profit Margin-15.05%
P/E Ratio9.3
ROE-16.39%
ROA-6.26%
Debt/Equity4.32
P/B Ratio0.6
Op. Cash Flow$20.1M
Free Cash Flow$27.0M
Industry P/E33.2
Technical Analysis
TrendBearish
RSI43.6
Support$0.69
Resistance$1.05
MA 20$0.85
MA 50$1.12
MA 200$1.64
MACDBullish
VolumeStable
Fear & Greed Index77.61
Valuation
Fair Value$4.53
Target Price$1.50
Upside/Downside72.10%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.15
Volatility106.97%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.